Adicet Bio to Present at Upcoming Investor Conferences

Rhea-AI Summary

Adicet Bio (NASDAQ: ACET), a clinical-stage biotechnology firm focused on allogeneic gamma delta CAR T cell therapies for cancer, announces management's participation in three investor conferences in August 2022. CEO Chen Schor will engage in a fireside chat at the BTIG Biotech Conference on August 8, participate in a virtual panel at the Wedbush Pacgrow Healthcare Conference on August 10, and present a corporate overview at the Canaccord Genuity Annual Growth Conference on August 11. Live webcasts will be accessible on the company’s investor website.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in three upcoming investor conferences in August.

Details of the events are as follows:

BTIG Biotech Conference, August 8-9, 2022

• Chen Schor, President & CEO, will participate in a fireside chat at the conference on Monday, August 8, 2022.

Wedbush Pacgrow Healthcare Conference, August 9-10, 2022

• Chen Schor, President & CEO, will participate in a virtual panel discussion titled, “A View to a Kill(er) Cell – Part 1” on Wednesday, August 10, 2022, at 1:10 P.M. ET.

Canaccord Genuity Annual Growth Conference, August 8-11, 2022, Boston, Massachusetts

• Chen Schor, President & CEO, will present a corporate overview on Thursday, August 11, 2022, at 11:00 A.M. ET.

The live audio webcast of the Canaccord Genuity presentation and Wedbush panel can be accessed on the Investors section of Adicet Bio’s website at https://investor.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005661/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

When will Adicet Bio participate in the BTIG Biotech Conference?

Adicet Bio will participate in the BTIG Biotech Conference on August 8-9, 2022, with CEO Chen Schor attending a fireside chat on August 8.

What is the schedule for Adicet Bio at the Wedbush Pacgrow Healthcare Conference?

At the Wedbush Pacgrow Healthcare Conference, Adicet Bio's CEO Chen Schor will join a virtual panel discussion on August 10, 2022, at 1:10 P.M. ET.

When is Adicet Bio's presentation at the Canaccord Genuity Annual Growth Conference?

Adicet Bio CEO Chen Schor will present a corporate overview on August 11, 2022, at 11:00 A.M. ET at the Canaccord Genuity Annual Growth Conference.

Where can I access the live webcasts for Adicet Bio's presentations?

Live webcasts for Adicet Bio's presentations can be accessed on the Investors section of their website at https://investor.adicetbio.com.

What does Adicet Bio focus on in its biotechnology research?

Adicet Bio focuses on developing allogeneic gamma delta T cell therapies for cancer, utilizing CAR and T cell receptor-like targeting to enhance tumor targeting.